यूरोपीय संघ - स्लोवाक - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminokyselinový metabolizmus, vrodené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminósýra efnaskipti, innfæddir villur - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminosyre-metabolisme, infiserte feil - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminohappoaineenvaihdunta, synnynnäiset virheet - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi-aventis farmacÊutica ltda - alfa-alglicosidase - enzima para reposiÇao

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

genzyme do brasil ltda - enzima para reposiÇao

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

relonchem ltd - furosemide - oral tablet - 20mg

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

celltrion healthcare new zealand limited - infliximab 120 mg/ml - solution for injection - 120 mg/ml - active: infliximab 120 mg/ml excipient: acetic acid polysorbate 80 sodium acetate trihydrate sorbitol water for injection - rheumatoid arthritis remsima sc, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: o adult patients with active disease when the response to disease-modifying antirheumatic drugs (dmards), including methotrexate, has been inadequate. o adult patients with severe, active and progressive disease not previously treated with methotrexate or other dmards. in these patient populations, a reduction in the rate of the progression of joint damage, as measured by x-ray, has been demonstrated (see section 5.1).

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - dexamethasone - oral tablet - 4mg